The group is a biopharmaceutical company operating through its subsidiaries: tanox pharma international inc, tanox pharma b.v. and tanasia pharma ltd. the group identifies and develops therapeutic monoclonal antibodies to treat unmet medical needs in the areas of asthma, allergy, autoimmune, inflammation and other related diseases. the group is also into developing the product xolairtm (tradename for omalizumab), an anti-immunoglobulin e, or anti-ige for treating patients suffering from allergic asthma, seasonal allergic rhinitis (hay fever) and perennial allergic. the product xolairtm is developed in collaboration with novartis pharma ag and genentech inc.